Endocrine & Metabolic Diseases

Endocrine & Metabolic Diseases

In Vivo Preclinical CRO Services at AniLocus for Endocrine Diseases and Metabolic Disorders

Unlock the potential of your endocrine disease therapeutics with AniLocus in vivo preclinical CRO services. Our team of experts specialize in in vivo research for pharmaceutical drug and medical device development. We offer tailored solutions to treat a wide range of endocrine diseases and metabolic disorders. With a deep understanding of the complexities involved, we implement comprehensive in vivo approaches for IND-enabling preclinical studies.

We are here to provide the highest quality research services, enabling you to advance novel drug development. Take the first step towards groundbreaking discoveries. Choose AniLocus for your preclinical needs.

Contact us! Learn more about our preclinical solutions: 

At Anilocus, we strive to offer quality, safety, and credibility to support your research efforts in the drug development process.

We conduct in vivo safety and efficacy assessments of therapeutics for multiple endocrine disease indications:

  • Hypercholesterolemia
  • Insulin Resistance
  • Metabolic Bone Disease (Osteoporosis)
  • Metabolic Syndrome
  • Non-Alcoholic Steatohepatitis (NASH)
  • Nonalcoholic Fatty Liver Disease (NAFLD)

How Can AniLocus Help You?

We are focused on whatever you need for your IND-enabling studies. Whether you need in vivo toxicology or efficacy evaluations, we can handle it!

We will work with your team to develop the study, protocols, and assign a scientific director to oversee the entire  study from start to finish. Contact us or reach out for a free consultation about our services.

Frequently Asked Questions

  • Gene Knockout/Gene Knock-in
  • Transgenic Rodents
  • Chemically-Induced Point Mutation rodents
  • Stress-Induced models
  • Drug-Induced models
  • Metabolically-induced models (Diet-induced, Metabolic disorder, micronutrient deficient)
  • And more…
  • Antibodies (nanobodies, monoclonal)
  • Gene therapy (CRISPR, TALEN)
  • Viral therapy (adenovirus-AAV, lentivirus)
  • Oligo- and polypeptides (e.g., stapled and modified peptides)
  • Oligo- and polynucleotides (e.g., siRNAs, mRNAs, aptamers)
  • Polyglycosides
  • Macrocyclic molecules
  • Drug conjugates (e.g., antibody–drug conjugates, drug-drug conjugates, fluorescence-labeled drugs)
  • Targeted protein degraders (e.g., proteolysis-targeting chimeras (PROTACs) and molecular glues) that induce a chemical knockdown of proteins
  • Cellular therapies (stem cells, allogenic, autologous)

The treatment endpoints that are typically analyzed in metabolic disease animal models are body weight, food intake, glucose tolerance, insulin sensitivity, and triglyceride levels. These endpoints are used to assess the effectiveness of treatments in metabolic diseases such as diabetes and obesity. Body weight is a key indicator of how well treatments are controlling the disease, while food intake and glucose tolerance tests measure the animal’s metabolic capability as a result of the treatment.

Insulin sensitivity tests measure the ability of the animal’s cells to respond to insulin and triglyceride levels measure the amount of fat stored in the liver. Study-specific endpoints will vary depending on the treatment, duration of the study, animal model selection, and study goals.

Assessing peptide therapeutics in vivo in animal models for rare endocrine disorders involves a number of steps. First, it is essential to determine the specific peptide or peptide combinations that will be tested. Next, the appropriate animal model should be selected based on the target mechanism of action and the nature of the rare endocrine disorder. Then, an appropriate dosing and delivery system should be established, and appropriate safety and efficacy parameters should be defined. Finally, the peptide therapeutics should be tested in the animal model to determine its efficacy.

Data analysis should include measuring changes in hormone levels, weight, body composition, and other relevant endpoints. After the testing is concluded, the results should be evaluated for safety and efficacy and further refinements should be made if necessary.

In order to initiate a successful dose-response pilot study in mouse models, we need a few key components. First, our team of scientists will consult with your team to determine the desired outcomes of the study. Once we’ve established the outcomes and data endpoints needed to answer the research questions, we will select a suitable animal model that is translationally relevant to the disease indication. Additionally, we will decide on an appropriate range of doses for the test article, formulation, and drug administration route, as well as a proper control article. Finally, we will have your team approve the study protocol and schedule that outlines the procedures and experimental timeline. With these components in place, we can begin your pilot study.

When assessing possible off-target effects of small molecule agonists in vivo in animal models of insulin resistance, it is important to consider the interactions between these molecules and their target receptors. In vivo studies can be used to evaluate the efficacy of small molecule agonists on the expression and activity of the target receptor. This can be done by examining changes in receptor expression levels, ligand binding, and downstream signaling pathways within various tissue.

Additionally, off-target effects can be evaluated by examining changes in the expression and activity of non-target receptors. This can be done by measuring changes in gene expression levels, ligand binding, or changes in receptor activation states. Finally, gene knock-out studies can be used to determine if a particular target receptor is involved in the observed phenotypes.